Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
Business Wire•07/10/2026•08:00 ET
0
Key Highlights
- ➤First patients enrolled in NYU Langone’s Signatera-guided melanoma trial
- ➤Advanced melanoma patients randomized after six weeks of first-line treatment
- ➤Signatera-positive patients receive continued therapy or added Ipilimumab
- ➤Primary endpoint is progression-free survival
Expert Statements
Janice M. Mehnert, M.D. and principal investigator of the study
“This trial takes a more proactive therapeutic approach from the standard of care, which is to treat with immunotherapy until evidence of radiographic progression”
Janice M. Mehnert, M.D. and principal investigator of the study
“By using Signatera to identify patients who do not clear ctDNA early in the treatment regimen, we can act sooner to escalate therapies for those who need it as we aim to improve outcomes.”
Michael Krainock, M.D., Ph.D., MBA and medical director, oncology, Natera
“We are pleased to collaborate with NYU Langone Health on this important trial in melanoma”
Michael Krainock, M.D., Ph.D., MBA and medical director, oncology, Natera
“By integrating Signatera into the trial design, we hope to improve patient selection for therapy escalation – distinguishing those who may be able to continue their current treatment without disease progression from others who need more intensified therapy.”
Michael Krainock, M.D., Ph.D., MBA and medical director, oncology, Natera
“If the results are positive, this could be an important step toward changing clinical practice patterns in how we manage melanoma.”
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
First patients enrolled in multi-center trial evaluating MRD-guided escalation for patients with advanced melanoma
Get started
Create a free account to read the full story.